Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report
oleh: Marco Sposito, MD, Ilaria Mariangela Scaglione, MD, Serena Eccher, MD, Luca Pasqualin, MD, Alice Avancini, PhD, Chiara Colato, MD, Paolo Rosina, MD, Michele Simbolo, PhD, Anna Caliò, MD, PhD, Aldo Scarpa, MD, Michele Milella, MD, Sara Pilotto, MD, PhD, Lorenzo Belluomini, MD
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2023-12-01 |
Deskripsi
Background: Enteric-type adenocarcinoma of the lung (lung-ETAC) is a rare form of lung cancer with histologic similarities to colorectal cancer, with aggressive behavior and unfavorable prognosis. Case Presentation: An 81-year-old man presented with discolored skin lesions on the chest and abdomen. After comprehensive evaluation, including skin biopsy and molecular profiling, the patient was diagnosed with having lung-ETAC with a BRAF p.V600E mutation. Treatment with dabrafenib and trametinib initially resulted in positive results, with improvement in skin lesions and overall clinical condition. Nevertheless, approximately 6 months after, the disease had progression with new skin lesions reappearing. Conclusions: We reported a unique case of a patient with BRAF p.V600E-mutant lung-ETAC with metastatic skin lesions achieving complete cutaneous response after targeted treatment with dabrafenib and trametinib, highlighting the potential for targeted therapy in patients with lung-ETAC harboring a BRAF p.V600E mutation.